Intellia Therapeutics, Inc.
NTLA
$12.33
$0.131.03%
NASDAQ
| 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | |
|---|---|---|---|---|---|
| Revenue | 66.09M | 67.67M | 57.53M | 52.86M | 45.57M |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 66.09M | 67.67M | 57.53M | 52.86M | 45.57M |
| Cost of Revenue | 313.85M | 341.54M | 367.56M | 397.79M | 417.69M |
| Gross Profit | -247.75M | -273.86M | -310.04M | -344.93M | -372.12M |
| SG&A Expenses | 172.96M | 167.13M | 168.69M | 167.09M | 168.95M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 486.81M | 508.66M | 536.26M | 564.88M | 586.64M |
| Operating Income | -420.72M | -440.99M | -478.73M | -512.02M | -541.07M |
| Income Before Tax | -394.60M | -412.69M | -445.81M | -480.19M | -525.91M |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -394.60 | -412.69 | -445.81 | -480.19 | -525.91 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -394.60M | -412.69M | -445.81M | -480.19M | -525.91M |
| EBIT | -420.72M | -440.99M | -478.73M | -512.02M | -541.07M |
| EBITDA | -411.24M | -431.22M | -468.77M | -501.87M | -530.80M |
| EPS Basic | -3.53 | -3.83 | -4.27 | -4.69 | -5.23 |
| Normalized Basic EPS | -2.21 | -2.39 | -2.66 | -2.89 | -3.09 |
| EPS Diluted | -3.53 | -3.83 | -4.27 | -4.69 | -5.23 |
| Normalized Diluted EPS | -2.21 | -2.39 | -2.66 | -2.89 | -3.09 |
| Average Basic Shares Outstanding | 448.33M | 433.34M | 419.28M | 410.09M | 403.33M |
| Average Diluted Shares Outstanding | 448.33M | 433.34M | 419.28M | 410.09M | 403.33M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |